METHOD FOR EVALUATING RISK IN MULTIPLE SCLEROSIS

摘要

The invention relates to methods and reagents for diagnosing and assessing the prognosis of multiple sclerosis. The present invention is based, in part, upon the discovery that anti-glycan antibodies are useful in evaluating the risk of whether clinically isolated syndrome (CIS) patients suggestive of Multiple sclerosis (MS) will have a clinical relapse within, e.g., 24 months. The invention is also based upon the discovery that anti-glycan antibodies are useful for evaluating the risk of CIS patients suggestive of MS to have a rapid disease progression and accumulate disabilities, e.g., permanent disability, within a certain time frame, e.g., 5 years.